ADAPTIVE BIOTECHNOLOGIES CORPORATION - COMMON STOC

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results

14 Feb 2024 15:05:54 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024

29 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference

27 Dec 2023 15:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting

09 Dec 2023 07:30:37 By Nasdaq GlobeNewswire

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting

05 Dec 2023 06:30:38 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update

09 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy Pipeline

07 Nov 2023 06:30:36 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023

02 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Adaptive Announces Launch of Epic Integration for clonoSEQ®

13 Sep 2023 06:30:49 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

30 Aug 2023 15:30:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports Second Quarter 2023 Financial Results

02 Aug 2023 15:05:54 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Second Quarter Financial Results on August 2, 2023

10 Jul 2023 15:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer

02 Jun 2023 06:34:30 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences

24 May 2023 15:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare Conference

12 May 2023 07:00:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology

09 May 2023 06:30:35 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports First Quarter 2023 Financial Results

03 May 2023 15:05:01 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in the BofA Securities 2023 Healthcare Conference

25 Apr 2023 15:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline

12 Apr 2023 06:30:43 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023

06 Apr 2023 15:05:00 By Nasdaq GlobeNewswire